India Pharmaceuticals Industry Report - H2, 2013
India Pharmaceutical & Healthcare provides an overview of the industry in Asia Pacific and India. India’s pharmaceutical industry grew by 9.7% year-on-year in 2009-2010, largely due to robust growth in the domestic market. India’s healthcare industry is expected to grow 14% per year to reach USD 280 billion by 2020. Exports of drugs, pharmaceuticals and fine chemicals accounted for approximately 4.20% of the total national exports in 2010-2011.
The report includes the market trends and outlook for the pharmaceutical and healthcare industries in India. We examine the country’s generic production, healthcare equipments, government schemes, TRIPS Compatibility, R&D initiatives, Pharmaceutical Export Promotion Council and India’s Vision 2015.
Also, the report encompasses the profile of leading players in the industry as well as their financial highlights and SWOT analysis. Among the leading players are Ranbaxy, Dr Reddy’s, Cipla and Lupin. Ranbaxy is India’s largest pharmaceutical company with operations in 23 of the top 25 pharmaceutical markets of the world.
Key Points:
The report includes the market trends and outlook for the pharmaceutical and healthcare industries in India. We examine the country’s generic production, healthcare equipments, government schemes, TRIPS Compatibility, R&D initiatives, Pharmaceutical Export Promotion Council and India’s Vision 2015.
Also, the report encompasses the profile of leading players in the industry as well as their financial highlights and SWOT analysis. Among the leading players are Ranbaxy, Dr Reddy’s, Cipla and Lupin. Ranbaxy is India’s largest pharmaceutical company with operations in 23 of the top 25 pharmaceutical markets of the world.
Key Points:
- India’s pharmaceutical industry grew by 9.7% year-on-year in 2009-2010, largely due to robust growth in the domestic market.
- India’s healthcare industry is expected to grow 14% per year to reach USD 280 billion by 2020.
- According to government statistics, exports of drugs, pharmaceuticals and fine chemicals throughout 2010-2011 stood at INR 47,551 cr after a robust growth of 12.0% over 2009-2010.
1. INDUSTRY PROFILE
1.1 Asia-Pacific Overview
1.2 General Overview of India
1.3 India Pharmaceutical Industry
1.3.1 Domestic Pharmaceutical Industry
1.3.2 Pharmaceutical Exports and Imports
1.3.3 Central Pharma Public Sector Undertakings (CPSUs)
2. MARKET TRENDS AND OUTLOOK
2.1 Indian Generics Production
2.2 Healthcare Equipment
2.3 Government Schemes
2.4 TRIPS Compatibility and India
2.5 Research and Development (R&D) Initiatives
2.6 Pharmaceuticals Export Promotion Council (Pharmexcil)
2.7 Vision 2015
3. LEADING PLAYERS AND COMPARATIVE MATRIX
3.1 Leading Players
3.1.1 Ranbaxy Laboratories Limited (Ranbaxy)
3.1.2 Dr Reddy’s Laboratories Limited (Dr Reddy’s)
3.1.3 Cipla Limited (Cipla)
3.1.4 Lupin Limited (Lupin)
3.2 Comparative Matrix
3.3 SWOT Analysis
4. TABLES AND CHARTS
Table 1: World Health Statistics
Table 2: Pharmaceutical Market Share in National Trade (figures in INR cr) (2006-07 – 2010-11)
Table 3: Comparison of International and Indian Prices of Generics Drugs
Table 4: Prices of Bulk Drugs
Table 5: Formulation Packs
Table 6: R&D Expenditures (1995-96 – 2009-10)
Table 7: Dr Reddy’s - Total Revenues by Segment (2010-11 – 2011-12)
Table 8: Financial Highlights of the Leading Players
Chart 1: Global Pharmaceutical Market by Region in 2011
Chart 2: Global Pharmaceutical Market by Region in 2008
Chart 3: India’s GDP by Sector (2006-2012)
Chart 4: State-wise Distribution of Pharmaceutical Units in India
Chart 5: India Pharmaceutical Sector (2005-06 – 2009-10)
Chart 6: Production and Sales of Pharma CPSUs (2008-09 – 2011-12)
Chart 7: Estimated Size of Medical Equipments Industry (2008-2012)
Chart 8: Indian Pharmaceutical Industry (2002-03 – 2015-16P)
Chart 9: Ranbaxy - Expenditure on R&D Operations (2008 – 2011)
Chart 10: Dr Reddy’s - Revenue Distribution by Geographical Mix (FY 2011 & FY 2012)
Chart 11: Cipla - Export Markets in FY 2012
Chart 12: Lupin - Operational Highlights (2008 - 2012)
Chart 13: Lupin - Revenue Breakdown in FY 2012
1.1 Asia-Pacific Overview
1.2 General Overview of India
1.3 India Pharmaceutical Industry
1.3.1 Domestic Pharmaceutical Industry
1.3.2 Pharmaceutical Exports and Imports
1.3.3 Central Pharma Public Sector Undertakings (CPSUs)
2. MARKET TRENDS AND OUTLOOK
2.1 Indian Generics Production
2.2 Healthcare Equipment
2.3 Government Schemes
2.4 TRIPS Compatibility and India
2.5 Research and Development (R&D) Initiatives
2.6 Pharmaceuticals Export Promotion Council (Pharmexcil)
2.7 Vision 2015
3. LEADING PLAYERS AND COMPARATIVE MATRIX
3.1 Leading Players
3.1.1 Ranbaxy Laboratories Limited (Ranbaxy)
3.1.2 Dr Reddy’s Laboratories Limited (Dr Reddy’s)
3.1.3 Cipla Limited (Cipla)
3.1.4 Lupin Limited (Lupin)
3.2 Comparative Matrix
3.3 SWOT Analysis
4. TABLES AND CHARTS
Table 1: World Health Statistics
Table 2: Pharmaceutical Market Share in National Trade (figures in INR cr) (2006-07 – 2010-11)
Table 3: Comparison of International and Indian Prices of Generics Drugs
Table 4: Prices of Bulk Drugs
Table 5: Formulation Packs
Table 6: R&D Expenditures (1995-96 – 2009-10)
Table 7: Dr Reddy’s - Total Revenues by Segment (2010-11 – 2011-12)
Table 8: Financial Highlights of the Leading Players
Chart 1: Global Pharmaceutical Market by Region in 2011
Chart 2: Global Pharmaceutical Market by Region in 2008
Chart 3: India’s GDP by Sector (2006-2012)
Chart 4: State-wise Distribution of Pharmaceutical Units in India
Chart 5: India Pharmaceutical Sector (2005-06 – 2009-10)
Chart 6: Production and Sales of Pharma CPSUs (2008-09 – 2011-12)
Chart 7: Estimated Size of Medical Equipments Industry (2008-2012)
Chart 8: Indian Pharmaceutical Industry (2002-03 – 2015-16P)
Chart 9: Ranbaxy - Expenditure on R&D Operations (2008 – 2011)
Chart 10: Dr Reddy’s - Revenue Distribution by Geographical Mix (FY 2011 & FY 2012)
Chart 11: Cipla - Export Markets in FY 2012
Chart 12: Lupin - Operational Highlights (2008 - 2012)
Chart 13: Lupin - Revenue Breakdown in FY 2012
